![Johannes Zanzinger](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Johannes Zanzinger
Directeur/Membre du Conseil chez
HepaRegeniX GmbH
Profil
Johannes Zanzinger is currently a Director at Eyevensys SAS, Metabomed Ltd., HepaRegeniX GmbH, and DiogenX SAS. He is also an Investor at Boehringer Ingelheim (Venture Capital).
Previously, he held Director positions at Centauri Therapeutics Ltd. and AgomAb Therapeutics NV.
He completed his undergraduate degree at the University of Hohenheim.
Postes actifs de Johannes Zanzinger
| Sociétés | Poste | Début |
|---|---|---|
HepaRegeniX GmbH
 HepaRegeniX GmbH BiotechnologyHealth Technology Operates as a clinical-stage biotechnology company that develops novel therapies for the treatment of acute and chronic liver diseases | Directeur/Membre du Conseil | - |
Boehringer Ingelheim (Venture Capital)
 Boehringer Ingelheim (Venture Capital) Investment ManagersFinance BIVF invests in companies located across the globe including the United States, Europe and China. The firm targets companies operating in groundbreaking innovation including cancer, regenerative medicine, auto-immunity indications, digital solutions and infectious disease. It participaotes in seed and early stage capital requirements. The firm acquires minority interest and makes follow-on investments. It also takes seat on the board of directors. | Private Equity Investor | 01/05/2019 |
Eyevensys SAS
 Eyevensys SAS Miscellaneous Commercial ServicesCommercial Services Develops non-viral gene therapy process for the treatment of ocular illnesses | Directeur/Membre du Conseil | - |
DiogenX SAS
 DiogenX SAS BiotechnologyHealth Technology Operates as preclinical stage biotech company, that engages in develops and research biologics therapeutics options for diabetic patients | Directeur/Membre du Conseil | - |
Metabomed Ltd.
 Metabomed Ltd. Pharmaceuticals: MajorHealth Technology Operates as a drug discovery company | Directeur/Membre du Conseil | - |
Anciens postes connus de Johannes Zanzinger
| Sociétés | Poste | Fin |
|---|---|---|
Centauri Therapeutics Ltd.
 Centauri Therapeutics Ltd. BiotechnologyHealth Technology Operates as an immunotherapy biotechnology company that engages in discovery and development of novel molecules targeting life threatening diseases | Directeur/Membre du Conseil | - |
| AGOMAB THERAPEUTICS NV | Directeur/Membre du Conseil | - |
Formation de Johannes Zanzinger
Expériences
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations
12
Relations au 1er degré
8
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 8 |
|---|---|
University of Hohenheim
 University of Hohenheim Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Boehringer Ingelheim (Venture Capital)
Boehringer Ingelheim (Venture Capital) Investment ManagersFinance BIVF invests in companies located across the globe including the United States, Europe and China. The firm targets companies operating in groundbreaking innovation including cancer, regenerative medicine, auto-immunity indications, digital solutions and infectious disease. It participaotes in seed and early stage capital requirements. The firm acquires minority interest and makes follow-on investments. It also takes seat on the board of directors. | Finance |
Eyevensys SAS
Eyevensys SAS Miscellaneous Commercial ServicesCommercial Services Develops non-viral gene therapy process for the treatment of ocular illnesses | Commercial Services |
Metabomed Ltd.
Metabomed Ltd. Pharmaceuticals: MajorHealth Technology Operates as a drug discovery company | Health Technology |
Centauri Therapeutics Ltd.
Centauri Therapeutics Ltd. BiotechnologyHealth Technology Operates as an immunotherapy biotechnology company that engages in discovery and development of novel molecules targeting life threatening diseases | Health Technology |
HepaRegeniX GmbH
HepaRegeniX GmbH BiotechnologyHealth Technology Operates as a clinical-stage biotechnology company that develops novel therapies for the treatment of acute and chronic liver diseases | Health Technology |
AgomAb Therapeutics NV
 AgomAb Therapeutics NV BiotechnologyHealth Technology Develops molecular therapies for regeneration of damaged tissues | Health Technology |
DiogenX SAS
DiogenX SAS BiotechnologyHealth Technology Operates as preclinical stage biotech company, that engages in develops and research biologics therapeutics options for diabetic patients | Health Technology |
Choisissez Zonebourse 
